- Marketwired•6 days ago
Prima BioMed Ltd today announced that the first patient has been dosed for the second cohort of its clinical trial program for IMP321 in combination with KEYTRUDA® being conducted in Australia. The second ...
- Marketwired•13 days ago
Prima BioMed Ltd , a leading immuno-oncology company, today announced that it has entered into a new collaboration agreement with Japan's CYTLIMIC, a recent spin off from NEC Corporation , to test a cancer ...
- Marketwired•15 days ago
Prima BioMed Ltd announces that it has developed a new early stage product candidate, a humanised IgG4 monoclonal antibody to be known as IMP761. This antibody, developed at the Company's laboratory in ...
PBMD : Summary for Prima BioMed Ltd - American Dep - Yahoo Finance
Prima Biomed Ltd. (PBMD)
NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
|Bid||2.38 x 600|
|Ask||2.69 x 2100|
|Day's Range||2.55 - 2.68|
|52 Week Range||0.51 - 3.26|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-4.14|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|